Tag Archives: section 3(d)
Attack on affordable medicines continues in EU-India trade negotiations
Attack on affordable medicines continues in EU-India trade negotiations Health groups rally in Delhi as protests spread across the developing world 10 April, 2013, New Delhi- Thousands of people living with HIV, cancer patient groups & public health activists rallied
Apex court right to reject Novartis’s attempt
Novartis threat that it would not introduce new medicines in India after the verdict is hollow, says Anand Grover. While the patients and the generic companies have rejoiced over the Supreme Court’s verdict in the Novartis case rejecting the patent
South Korean civil society groups welcome the ruling of the Supreme Court of India
[Novartis defeated in its appeal trial, a triumphant victory of World patients fighting back Patent Exclusivity] Welcome the ruling of the Supreme Court of India 1. The protracted Novartis’ appeal from 2006 for a patent to Gleevec (Leukemia medicine), and
Strictest patent laws will foster genuine innovation
In 2005, as the Indian Parliament debated at length the impact of complying with the WTO’s TRIPS Agreement, one issue was uppermost in their minds; the impact of granting patents on access to affordable generic medicines. And, the one medicine
Glivec ruling: Putting patients before profits
Supreme Court’s verdict on Glivec benefits not just millions in India, but across the developing world Anand Grover Novartis’s assertions that the ruling will affect investment or future innovations have been belied time and again, including at the World Health
Novartis case: Supreme Court’s historic decision on Section 3(d)
Anand Grover | Apr 2, 2013, 03.11 AM IST After 2005 India started granting product patents on medicines. However, Section 3(d), one of the safeguards introduced by Parliament, seeks to prevent patenting of new forms of known substances unless they
Hope for hep-c patients: Patients succeed in overturning first ever product patent on medicine in India
2 November 2012, New Delhi. In a landmark victory for patients’ groups fighting against patents to ensure access to medicines, the Intellectual Property Appellate Board (IPAB) has revoked a patent granted in India to F. Hoffmann-La Roche AG (Roche) for
Hearing Update: Novartis argues section 3(d) not intended to address issue of access to medicines
13 September 2012, New Delhi. Mr Subramaniam, senior counsel appearing for Novartis, continued his arguments today. Placing on record the Doha Declaration on TRIPS Agreement and Public Health, Mr Subramaniam said that it is important to bear in mind the
